Seer (SEER) Competitors

Seer (NASDAQ:SEER) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Do analysts prefer SEER or LAB?

Seer presently has a consensus target price of $3.00, suggesting a potential upside of 38.89%. Standard BioTools has a consensus target price of $2.50, suggesting a potential upside of 132.56%. Given Standard BioTools' stronger consensus rating and higher probable upside, analysts clearly believe Standard BioTools is more favorable than Seer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Standard BioTools	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Do institutionals & insiders have more ownership in SEER or LAB?

75.2% of Seer shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 11.3% of Seer shares are owned by company insiders. Comparatively, 23.2% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has higher earnings and valuation, SEER or LAB?

Standard BioTools has higher revenue and earnings than Seer. Standard BioTools is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$15.06M	8.44	-$86.28M	-$1.41	-1.53
Standard BioTools	$169.69M	2.41	-$74.66M	-$0.35	-3.07

Does the media refer more to SEER or LAB?

In the previous week, Seer had 3 more articles in the media than Standard BioTools. MarketBeat recorded 5 mentions for Seer and 2 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.85 beat Seer's score of 0.48 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seer	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Standard BioTools	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk and volatility, SEER or LAB?

Seer has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

Is SEER or LAB more profitable?

Standard BioTools has a net margin of -79.92% compared to Seer's net margin of -565.83%. Seer's return on equity of -21.96% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-565.83%	-21.96%	-19.85%
Standard BioTools	-79.92%	-27.05%	-15.52%

Does the MarketBeat Community prefer SEER or LAB?

Standard BioTools received 2 more outperform votes than Seer when rated by MarketBeat users. Likewise, 83.33% of users gave Standard BioTools an outperform vote while only 13.64% of users gave Seer an outperform vote.

Company	Underperform	Outperform
Seer	Outperform Votes 3 13.64%	Underperform Votes 19 86.36%
Standard BioTools	Outperform Votes 5 83.33%	Underperform Votes 1 16.67%

Summary

Standard BioTools beats Seer on 13 of the 18 factors compared between the two stocks.